Eléments de l'association

	H. Nakamae	1
	Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)	4
	H. Nakamae *Sauf* Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)"	0
	Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) *Sauf* H. Nakamae"	3
	H. Nakamae Et Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)	1
	H. Nakamae Ou Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)	4
	*Corpus*	4588

List of bibliographic references

Number of relevant bibliographic references: 1.

Ident.	Authors (with country if any)	Title
000803	A. Hochhaus [Allemagne] ; G. Saglio [Italie] ; T P Hughes [Australie] ; R A Larson [États-Unis] ; D-W Kim [Corée du Sud] ; S. Issaragrisil [Thaïlande] ; P D Le Coutre [Allemagne] ; G. Etienne [France] ; P E Dorlhiac-Llacer [Brésil] ; R E Clark [Royaume-Uni] ; I W Flinn [États-Unis] ; H. Nakamae [Japon] ; B. Donohue [États-Unis] ; W. Deng [États-Unis] ; D. Dalal [États-Unis] ; H D Menssen [Suisse] ; H M Kantarjian [États-Unis]	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024